Advancements and Insights in Non–Muscle-Invasive Bladder Cancer: Emerging PD-1/PD-L1 Inhibitors
Panelists discuss how emerging PD-1 and PD-L1 inhibitors could transform the treatment landscape for non–muscle-invasive bladder cancer, highlighting the importance of a multidisciplinary approach and ongoing clinical trials for high-risk patients.
EP. 1: Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging
Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) presents with specific symptoms and diagnostic procedures, emphasize the significant economic burden on health care systems, and highlight key risk factors like smoking and occupational exposure while also addressing the critical importance of accurate staging for guiding treatment decisions and the potential consequences of incorrect staging on patient outcomes.
EP. 2: NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes
Panelists discuss how standard treatment options for non–muscle-invasive bladder cancer (NMIBC) include BCG therapy, exploring its mechanism of action in enhancing the immune response while also examining management strategies for intermediate and high-risk patients, optimal outcomes with single-agent BCG, and the discrepancies between observed rates of recurrence and progression in clinical practice and reported data.
